Alibaba has banned employee use of Anthropic's Claude tools starting July 10 and placed Claude Code on a high-risk list after Anthropic accused it of the largest known distillation attack. The move highlights escalating restrictions on U.S. AI models in China amid terms-of-service bans and reported access loopholes.
Employees must remove all Anthropic models and agent products and switch to the company's own AI assistant, Qoder.
The U.S. firm's terms of service ban Chinese companies and other "adversarial nations" from using its models.
Tap a lens to see what this story means for you.
Reader-supported · Daily Brief
Daily brief at 7 AM ET. Top tech stories, every morning. Sourced and fact-checked.
See what’s happening right now
The Feed runs all day — short, verified briefs the moment they break.
Open the FeedFollow @thecircuitry_
Every story we publish, as it happens. No noise between.
Reader-supported
The Circuitry is a passion project I've always wanted to build, and I love the work behind it.
Running it costs real money. APIs, hosting, time. To keep improving the site and growing this into something useful for everyone, those costs have to be covered.
Any contribution is appreciated. If not, no pressure. Thanks for reading.
ByteDance's Doubao and Alibaba's Qwen are disabling humanlike agent features ahead of Beijing's Interim Measures for the Administration of AI Anthropomorphic Interaction Services, effective July 15. The regulation is the first to specifically ban services simulating sustained emotional interaction, including AI companions.
The FCC will vote on July 22 to drop the mandate that ISPs itemize all passthrough fees on broadband labels, permitting a single "up to" figure instead, while also reducing label visibility. The step reverses a Biden-era revision and fits Chairman Brendan Carr’s pattern of easing regulatory demands on carriers.
Kia will stop building its K9 luxury sedan after 14 years to concentrate on smaller, more affordable electric vehicles. The model launched in 2012 as successor to the Opirus; sales have declined since 2022 and are projected to reach an all-time low in 2026.
